Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Batlevi, C.
45  Ergebnisse:
Personensuche X
?
1

SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VE..:

Pavlovsky, A. ; Westin, J. ; Olszewski, A. J...
Hematological Oncology.  41 (2023)  S2 - p. 170-171 , 2023
Link: https://doi.org/10.1002/..
 
?
2

Patterns of Relapse and Risk Reduction Following Tumor Debu..:

Hubbeling, H.G. ; Silverman, E.A. ; Michaud, L....
International Journal of Radiation Oncology*Biology*Physics.  114 (2022)  3 - p. S135-S136 , 2022
Link: https://doi.org/10.1016/..
 
?
3

Radiotherapy for Relapse after Chimeric Antigen Receptor T ..:

Hubbeling, H.G. ; Silverman, E.A. ; Tomas, A. Alarcon...
International Journal of Radiation Oncology*Biology*Physics.  114 (2022)  3 - p. S56-S57 , 2022
Link: https://doi.org/10.1016/..
 
?
4

BENDAMUSTINE, RITUXIMAB, AND POLATUZUMAB VEDOTIN FOR RELAPS..:

Farina, K. A ; Drill, E ; Buie, L. W...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
5

CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAG..:

Sha, F. ; Okwali, M. ; Alperovich, A....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
6

PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VE..:

Kumar, A. ; Batlevi, C. ; Drullinsky, P....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
7

CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL R..:

Batlevi, C. L. ; Salles, G. ; Tilly, H....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
8

CR4 RESOURCE UTILIZATION WITHIN 30 DAYS OF CAR T CELLS FOR ..:

Shah, G. ; Park, J. ; Sauter, C....
Value in Health.  22 (2019)  - p. S38 , 2019
Link: https://doi.org/10.1016/..
 
?
9

CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LA..:

Bobillo, S. ; Joffe, E. ; Lavery, J....
Hematological Oncology.  37 (2019)  S2 - p. 251-252 , 2019
Link: https://doi.org/10.1002/..
 
?
10

INCIDENCE AND TREATMENT OUTCOMES OF PATIENTS WITH TRANSFORM..:

Rajeeve, S. ; Bobillo, S.V. ; Zelenetz, A.D....
Hematological Oncology.  37 (2019)  S2 - p. 264-266 , 2019
Link: https://doi.org/10.1002/..
 
?
11

MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STR..:

Imber, B.S. ; Palomba, M.L. ; DeSelm, C....
Hematological Oncology.  37 (2019)  S2 - p. 259-261 , 2019
Link: https://doi.org/10.1002/..
 
?
12

PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL "ARMO..:

Batlevi, C.L. ; Palomba, M.L. ; Park, J....
Hematological Oncology.  37 (2019)  S2 - p. 166-167 , 2019
Link: https://doi.org/10.1002/..
 
?
13

SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMA..:

Sermer, D. ; Vardhana, S. ; Batlevi, C....
Hematological Oncology.  37 (2019)  S2 - p. 331-332 , 2019
Link: https://doi.org/10.1002/..
 
?
14

DOSE FINDING STUDY TO ASSESS SAFETY, PK AND EFFICACY OF FIM..:

Younes, A. ; Batlevi, C.L. ; Cohen, J.B....
Hematological Oncology.  37 (2019)  S2 - p. 561-562 , 2019
Link: https://doi.org/10.1002/..
 
?
15

IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE ..:

Batlevi, C.L. ; Sha, F. ; Alperovich, A....
Hematological Oncology.  37 (2019)  S2 - p. 152-153 , 2019
Link: https://doi.org/10.1002/..
 
1-15